From Lab Code to FDA Breakthrough Device

The Problem

Malignant cerebral edema is a life-threatening complication after a large ischemic stroke, and catching it early is one of the harder calls in neurocritical care. A care team that sees it coming can escalate monitoring or move to decompressive surgery before irreversible deterioration sets in.

BEACON-Neuro.AI Inc., a Washington University in St. Louis startup built on the clinical science of Dr. Raj Dhar's neurocritical-care lab at WashU Medicine, developed BEACONPredict: AI software that analyzes early brain-imaging changes alongside clinical variables and returns a risk estimate that supports the clinician's decision-making. The science was ready. What the team needed was an FDA-accepted route from research prototype to medical device — expertise outside a research lab.

The Outcome

• FDA Breakthrough Device Designation granted on the first review cycle.
• Acceptance into FDA's TAP pilot, providing enhanced FDA engagement and a potentially accelerated CMS NTAP reimbursement pathway after marketing authorization.
• A De Novo pathway underway, positioning BEACONPredict as a clinical decision support tool.
• BEACONPredict advanced from lab code to FDA Breakthrough Device in a single submission cycle.

The Timeline

• Engagement: Innolitics provided regulatory strategy and software engineering; BEACON-Neuro.AI contributed the clinical science.
• First review cycle: FDA granted Breakthrough Device Designation with no additional review cycles needed.
• Now: De Novo classification underway, with TAP pilot engagement. BEACON-Neuro.AI is raising pre-seed and seed funding to carry BEACONPredict through FDA clearance and commercial launch.

The Solution

Breakthrough Device Designation on the first attempt is not a matter of good science alone — it comes from aligning the clinical evidence plan and the regulatory strategy before anything is submitted. Innolitics established the De Novo route as a clinical decision support tool, planned the clinical and regulatory story as one document set, and engineered the software to match.

Breakthrough Device Designation is a premarket program, not a marketing authorization; BEACONPredict is not yet cleared or approved for commercial distribution.

Read the full announcement: Innolitics and BEACON-Neuro.AI Partner to Bring FDA Breakthrough Device BEACONPredict to Market